retatrutide what is retatrutide clinical trials UK: 2026 Trial & Approval Guide – Trim Retatrutide, an investigational triple hormone

This dual incretin signaling is what makes tirzepatide biologically distinct from semaglutide

Tirzepatide and semaglutide are generally safe, but they may not be suitable for everyone, including: People with a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) People with a personal or family history of pancreatitis People with known hypersensitivity to any component of the medication People who are pregnant, breastfeeding, and planning to become pregnant Always consult a healthcare provider before starting a new medication

Eden Health has paused its compounded GLP-1 program (both semaglutide and tirzepatide) for new patient enrollment as of mid-2026

In addition GLP-1 modulates dopamine levels and glutamatergic neuro-transmission, which results in observed behavioural changes